Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OPKO HEALTH, INC.

(OPK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
4.35(c) 4.27(c) 4.25(c) 4.31(c) 4.13(c) Last
2 596 600 3 203 628 4 532 895 2 916 587 3 457 626 Volume
+0.93% -1.84% -0.47% +1.41% -4.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 689 M - -
Net income 2021 25,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 103x
Yield 2021 -
Sales 2022 1 345 M - -
Net income 2022 32,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 82,6x
Yield 2022 -
Capitalization 2 813 M 2 813 M -
Capi. / Sales 2021 1,67x
Capi. / Sales 2022 2,09x
Nbr of Employees 5 269
Free-Float 59,5%
More Financials
Company
OPKO Health, Inc. is a healthcare company. Its segments include Diagnostics and Pharmaceutical. The Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions,... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Ratings of OPKO Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about OPKO HEALTH, INC.
11/10HealthSnap, Inc. announced that it has received $5 million in funding from OPKO Health,..
CI
11/05ASN Kidney Week 2021 Oral abstract presentation- Initial Evaluation of High-Dose Extend..
PU
10/29Opko Health Reports Flat Q3 Profit, Revenue Drops
MT
10/29Immediate Report
PU
10/28OPKO HEALTH : Q3 Earnings Snapshot
AQ
10/28OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results - Form..
PU
10/28OPKO Health, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021
CI
10/28OPKO HEALTH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
10/28Earnings Flash (OPK) OPKO HEALTH Posts Q3 Revenue $385.8M, vs. Street Est of $302.3M
MT
10/28OPKO Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
10/28OPKO HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
10/28OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
AQ
10/25OPKO HEALTH : to Report Third Quarter 2021 Financial Results on October 28, 2021
GL
10/25OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021
GL
10/12KRYSTAL BIOTECH : GeneDx to Offer Free Genetic Testing for Dystrophic Epidermolysis Bullos..
MT
More news
News in other languages on OPKO HEALTH, INC.
10/29Opko Health annonce un bénéfice stable au troisième trimestre et une baisse des recette..
10/28OPKO Health, Inc. fournit des prévisions de résultats pour le quatrième trimestre de 20..
10/28Earnings Flash (OPK) OPKO HEALTH affiche un chiffre d'affaires de 385,8 millions de dol..
10/12Krystal Biotech et GeneDx proposent des tests génétiques gratuits pour l'épidermolyse b..
08/30Opko Health achève le recrutement de 171 sujets pour l'étude de phase 2 COVID-19
More news
Analyst Recommendations on OPKO HEALTH, INC.
More recommendations
Chart OPKO HEALTH, INC.
Duration : Period :
OPKO Health, Inc. Technical Analysis Chart | OPK | US68375N1037 | MarketScreener
Technical analysis trends OPKO HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 4,13 $
Average target price 6,70 $
Spread / Average Target 62,2%
EPS Revisions
Managers and Directors
Phillip Frost Chairman & Chief Executive Officer
Jon Roger Cohen Director & Senior Vice President
Adam E. Logal CFO, Treasurer, Chief Accounting Officer & SVP
Jane H. Hsaio Vice Chairman & Chief Technical Officer
Steven D. Rubin Director & Executive Vice President-Administration
Sector and Competitors
1st jan.Capi. (M$)
OPKO HEALTH, INC.4.56%2 813
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049